← All organizations
Highest phase reached
Phase 4
First clinical trial
Oct 1, 1997Last known activity
Jul 1, 2026
Timeline
1930s
- Jun 1, 1937
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.— Founded
Drugs by trial phase (23 distinct, 25 trials)
Phase 4 (4 own, 0 via acquisition)
Phase 3 (8 own, 0 via acquisition)
Phase 2 (8 own, 0 via acquisition)
Phase 1 (1 own, 0 via acquisition)
Other trials (2 own, 0 via acquisition)
Indications
Studied for
- Adrenoleukodystrophy
- Anxiety Disorders
- Autism Spectrum Disorder
- Autistic Disorder
- Brain Stem Infarctions
- Child Development Disorders, Pervasive
- Cognitive Dysfunction
- Down Syndrome
- Epilepsy
- Fragile X Syndrome
- Hyperkinesis
- Klippel-Trenaunay-Weber Syndrome
- Muscular Dystrophies
- Muscular Dystrophy, Duchenne
- Osteogenesis Imperfecta
- Pseudohypoparathyroidism
- Pseudopseudohypoparathyroidism
- Rett Syndrome
- Schizophrenia
- Sclerosis
- Self-Injurious Behavior
- Sturge-Weber Syndrome
- Syndrome
- Tuberous Sclerosis
Recent trials (48)
- NCT07221968Lead sponsorPhase 2Jul 1, 2026
- NCT07221968Sponsor investigatorPhase 2Jul 1, 2026
- NCT07061470OfficialPhase 1/Phase 2Mar 1, 2026
- NCT07061470Lead sponsorPhase 1/Phase 2Mar 1, 2026
- NCT05324449Lead sponsorPhase 4Apr 5, 2022
- NCT05324449Reponsible party - principal investigatorPhase 4Apr 5, 2022
- NCT04421248CollaboratorPhase 4Sep 1, 2020
- NCT04421248Overall official - principal investigatorPhase 4Sep 1, 2020
- NCT04447846Lead sponsorPhase 2Oct 14, 2019
- NCT04447846Overall official - principal investigatorPhase 2Oct 14, 2019
- NCT04447846Sponsor investigatorPhase 2Oct 14, 2019
- NCT03371836Reponsible party - principal investigatorPhase 4Oct 1, 2017
- NCT03371836Overall official - principal investigatorPhase 4Oct 1, 2017
- NCT03371836Lead sponsorPhase 4Oct 1, 2017
- NCT03064074CollaboratorPhase 1Apr 1, 2017
Details
- Founded
- Baltimore, MD, US Jun 1, 1937
- Last known activity
- Jul 1, 2026